Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor 1 Secretion by CJC-1295, a Long-Acting Analog of Growth Hormone-Releasing Hormone
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA
Journal of Clinical Endocrinology & Metabolism · Vol. 91(3) · pp. 799–805 · 2006
Phase II clinical trial demonstrating that CJC-1295 produces dose-dependent increases in GH and IGF-1 levels in healthy adults. A single injection produced sustained GH elevation for 6 days and IGF-1 elevation for up to 14 days. The study established the safety and pharmacokinetic profile of CJC-1295 in humans.
Citation
Key Findings
Single injection of CJC-1295 increased mean GH levels by 2–10 fold for 6 days
IGF-1 levels increased 1.5–3 fold and remained elevated for up to 14 days
Dose-dependent response observed across 30–120 mcg/kg doses
Well tolerated with no serious adverse events in 66 healthy adults
Maintains pulsatile GH release pattern, avoiding receptor desensitization
Methodology
Randomized, double-blind, placebo-controlled Phase II clinical trial in 66 healthy adults aged 21–61. Multiple dose cohorts with serial GH and IGF-1 measurements.
Limitations
Short-term study (28 days); long-term effects not assessed. Healthy adult population only.
Protocols Using This Research
Tags
Educational use only. Research summaries are provided for informational purposes. Always consult the original publication and a qualified healthcare provider before making clinical decisions.
Build a protocol around this research
Our AI Advisor incorporates the latest research to build a personalized peptide protocol for your goals.
Start Assessment